ArticleDermatology and therapy2023
The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata.
Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06802705 (The Impact of Psychosocial Stress on Quality of Life in Saudi Arabian Patients With Alopecia Areata), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Psychosocial Stress on Quality of Life in Saudi Arabian Patients With Alopecia Areata
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- A systematic review and meta-synthesis of qualitative studies of alopecia: Managing identity and appearance changes.British journal of health psychology · 2026Pooled it
- Pooled it
- Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3.International journal of dermatology · 2026Trial
- Identifying and addressing obstacles to optimal alopecia areata and atopic dermatitis care in the UK.Skin health and disease · 2026Article
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata.Advances in therapy · 2026Article
- Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA.Dermatology and therapy · 2026Article
- Illness Perception, Emotional Distress, and Obsessive-Compulsive Symptomatology in Patients with Alopecia Areata: A Mediation Study.Behavioral sciences (Basel, Switzerland) · 2026Article
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Beyond skin deep: self-compassion mediates the link between body shame and psychopathology in people with alopecia and psoriasis.Health psychology report · 2026Article
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients-Results From an Australian Expert Consensus Exercise.The Australasian journal of dermatology · 2025Article
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement.The Australasian journal of dermatology · 2025Article
- Is Spontaneous Regrowth in Alopecia Areata Possible: A Systematic Review and Meta-analysis of Placebo-controlled Studies.Acta dermato-venereologica · 2025Article
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.Aesthetic plastic surgery · 2025Review
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.Cureus · 2025Review
- Local Corticosteroids for Alopecia Areata: A Narrative Review.Dermatology and therapy · 2025Review
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata.Dermatology and therapy · 2025Article
- Perceived Stigma Among Adults With Alopecia Areata in the United States.The Journal of dermatology · 2025Article
- 20 years of the socioeconomic impact of atopic dermatitis and alopecia areata from around the globe.Clinical and translational allergy · 2025Review
- Responsiveness of the Dermatology Life Quality Index and the Colombian Validated Version of the Skindex-29 in Scarring and Non-Scarring Alopecia.Skin appendage disorders · 2025Article
- Patient characteristics and patterns of treatment for moderate to severe alopecia areata: a single-institution retrospective study.Archives of dermatological research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe physical impact of alopecia areata (AA) is visible, but the psychological and social consequences and emotional burden are often underrecognized.
methodsIn this cross-sectional study, 547 participants recruited via the National Alopecia Areata Foundation completed a survey encompassing demographics; AA illness characteristics; and five patient-reported outcome measures on anxiety and depression, perceived stress, psychological illness impact, stigma, and quality of life (QoL). Differences in disease severity subgroups were assessed via analysis of variance (ANOVA) and t tests.
resultsMean age was 44.6 years, and 76.6% were female. Participants with more severe hair loss tended to report longer duration of experiencing AA symptoms (P < 0.001). Overall, participants reported negative psychological impact, emotional burden, and poor QoL due to AA. Participants with 21-49% or 50-94% scalp hair loss reported greater psychological impact and poorer QoL than those with 95-100% scalp hair loss (most parameters P < 0.05). Similar results were observed for eyebrow/eyelash involvement subgroups.
conclusionsThese results suggest that participants with AA experience emotional burden, negative self-perception, and stigma, but the impact of AA is not dependent solely on the amount of hair loss. Lower impact among participants with 95-100% scalp hair loss may indicate that they have adapted to living with AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.